Does antiretroviral therapy prevent HIV transmission to sexual partners?

Current Infectious Disease Reports

Volumn 10, Issue 2, 2008, Pages 140-145

  Lalani, Tahaniyat ^b   Hicks, Charles ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PLACEBO; TENOFOVIR;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG MECHANISM; DRUG RESPONSE; HETEROSEXUALITY; HIGH RISK BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PATIENT ATTITUDE; PATIENT COMPLIANCE; REVIEW; RISK REDUCTION; SEROCONVERSION; SEXUAL BEHAVIOR; SEXUALITY; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS SHEDDING; VIRUS TRANSMISSION;

EID: 56349159162     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-008-0025-8     Document Type: Review

References (39)

1. Joint United Nations Programme on HIV/AIDS, World Heath Organization: AIDS Epidemic Update: December 2006. http://www.unaids.org/en/ HIV_data/epi2006/. Accessed January 31, 2007.
2. Royce RA, Sena A, Cates W Jr, Cohen MS: Sexual transmission of HIV. N Engl J Med 1997, 336:1072-1078.
3. De Vincenzi I, for the European Group on Heterosexual Transmission of HIV: A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. N Engl J Med 1994, 331:341-346.
4. Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000, 342:921-929.
5. Pedraza MA, del Romero J, Roldan F, et al.: Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. J Acquir Immune Defic Syndr 1999, 21:120-125.
6. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173-1180.
7. Cardo DM, Culver DH, Ciesielski CA, et al.: A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997, 337:1485-1490.
8. Fang G, Burger H, Grimson R, et al.: Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci U S A 1995, 92:12100-12104.
9. Lee TH, Sakahara N, Fiebig E, et al.: Correlation of HIV-1 RNA levels in plasma and heterosexual transmission of HIV-1 from infected transfusion recipients. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 12:427-428.
10. Musicco M, Lazzarin A, Nicolosi A, et al.: Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med 1994, 154:1971-1976.
11. Tovanabutra S, Robison V, Wongtrakul J, et al.: Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002, 29:275-283.
12. Blower SM, Gershengorn HB, Grant RM: A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000, 287:650-654.
13. Velasco-Hernandez JX, Gershengorn HB, Blower SM: Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002, 2:487-493.
14. Chan DJ: Pathophysiology of HIV-1 in semen: current evidence for compartmentalisation and penetration by antiretroviral drugs. Curr HIV Res 2005, 3:207-222.
15. Cu-Uvin S, Snyder B, Harwell JI, et al.: Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr 2006, 42:584-587.
16. Vettore MV, Schechter M, Melo MF, et al.: Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy. J Infect 2006, 52:290-293.
17. Winter AJ, Taylor S, Workman J, et al.: Asymptomatic urethritis and detection of HIV-1 RNA in seminal plasma. Sex Transm Infect 1999, 75:261-263.
18. Pilcher C, Chilongozi D, Martinson F, et al.: Comparison of the concentration of HIV in semen during acute, early and late HIV infection: evaluation of the risk of the sexual transmission of HIV. Paper presented at the 16th International AIDS Conference. Toronto, Canada; August 13-18, 2006.
19. McClelland RS, Baeten JM, Richardson BA, et al.: A comparison of genital HIV-1 shedding and sexual risk behavior among Kenyan women based on eligibility for initiation of HAART according to WHO guidelines. J Acquir Immune Defic Syndr 2006, 41:611-615
20. Castilla J, Del Romero J, Hernando V, et al.: Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005, 40:96-101.
21. Melo M, Varella I, Lira R, et al.: Demographic characteristics, sexual transmission and CD4 progression among heterosexual HIV-1 serodiscordant couples followed in Porto Alegre, Brazil. Paper presented at the 16th International AIDS Conference. Toronto, Canada; August 13-18, 2006.
22. Kayitenkore K, Bekan B, Rufagari J, Marion-Landais S, et al.: The impact of ART on HIV transmission among HIV serodiscordant couples. Paper presented at the 16th International AIDS Conference. Toronto, Canada; August 13-18, 2006.
23. Barreiro P, del Romero J, Leal M, et al.: Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr 2006, 43:324-326.
24. Montaner JS, Hogg R, Wood E, et al.: The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006, 368:531-536.
25. Huebner DM, Gerend MA: The relation between beliefs about drug treatments for HIV and sexual risk behavior in gay and bisexual men. Ann Behav Med 2001,23:304-312.
26. Kalichman SC, Nachimson D, Cherry C, Williams E: AIDS treatment advances and behavioral prevention setbacks: preliminary assessment of reduced perceived threat of HIV-AIDS. Health Psychol 1998, 17:546-550.
27. Vanable PA, Ostrow DC, McKirnan DJ, et al.: Impact of combination therapies on HIV risk perceptions and sexual risk among HIV-positive and HIV-negative gay and bisexual men. Health Psychol 2000, 19:134-145.
28. Kalichman SC, Eaton L, Cain D, et al.: HIV treatment beliefs and sexual transmission risk behaviors among HIV positive men and women. J Behav Med 2006, 29:401-410.
29. Mascolini M: HIV rates are no longer falling in parts of Uganda. Paper presented at the 16th International AIDS Conference. Toronto, Canada; August 13-18, 2006.
30. Bunnell R, Wamai N, Ekwaru JP, et al.: Changes in sexual behavior and risk of HIV transmission after two years of antiretroviral therapy and prevention interventions in rural Uganda. Paper presented at the 16th International AIDS Conference. Toronto, Canada; August 13-18, 2006.
31. Fang CT, Hsu HM, Twu SJ, et al.: Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004, 190:879-885.
32. McCormick AW, Walensky RP, Lipstich M, et al.: The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Paper presented at the 16th International AIDS Conference. Toronto, Canada; August 13-18, 2006.
33. Centers for Disease Control and Prevention: Advancing HIV prevention: new strategies for a changing epidemic - United States, 2003. MMWR Morb Mortal Wkly Rep 2003, 52:329-332.
34. Hosseinipour M, Cohen MS, Vernazza PL, Kashuba AD: Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1? Clin Infect Dis 2002, 34:1391-1395.
35. Garcia-Lerma J, Otten R, Qari S, et al.: Prevention of rectal SHIV transmission in macaques by tenofovir/FTC combination. Paper presented at the 13th Conference of Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
36. Kellerman S, Hutchinson A, Begley E, et al.: Knowledge and use of pre-exposure prophylaxis among attendees of minority gay pride events, 2004. Paper presented at the 16th International AIDS Conference. Toronto, Canada; August 13-18, 2006.
37. Page-Shafer K, Saphonn V, Sun LP, et al.: HIV prevention research in a resource-limited setting: the experience of planning a trial in Cambodia. Lancet 2005, 366:1499-1503.
38. Otten RA, Smith DK, Adams DR, et al.: Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000, 74:9771-9775.
39. Peterson L, Taylor D, Clarke EEK, et al.: Safety and preliminary effectiveness of tenofovir disoproxil fumarate (TDF) for prevention of HIV infection in women [abstract]. Paper presented at the 16th International AIDS Conference. Toronto, Canada; August 13-18, 2006.